← All trials
NCT06738407
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 15, 2025
- Primary completion
- Jun 30, 2027
- Completion date
- Jun 30, 2028
- First posted
- Dec 17, 2024
- Last posted
- Dec 20, 2024
- Enrollment
- 760
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- WestatLead sponsor
- National Institutes of Health (NIH)Collaborator
- National Institute of Mental Health (NIMH)Collaborator
- National Institutes of Health (NIH)Collaborator
- National Institute on Drug Abuse (NIDA)Collaborator
- University of California, Los AngelesOfficial
- Florida State UniversityCollaborator
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- Hennepin HealthcareOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.